Search Results - Jackisch, C.
- Showing 1 - 5 results of 5
-
1
Conditional progression-free survival in patients with metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with first-line... by Decker, Thomas (Author) , Brucker, C. (Author) , Engel, A. (Author) , Fasching, P. A. (Author) , Göhler, T. (Author) , Jackisch, C. (Author) , Janssen, J. (Author) , Köhler, A. (Author) , Lüdtke-Heckenkamp, K. (Author) , Lüftner, Diana (Author) , Marmé, Frederik (Author) , van Mackelenbergh, M. (Author) , Rautenberg, B. (Author) , Schmidt, M. (Author) , Weide, R. (Author) , Wimberger, Pauline (Author) , Kisseleff, E. (Author) , Pfister, C. (Author) , Roos, C. (Author) , Wilhelm, N. (Author) , Wöckel, A. (Author) ,
Call Number: Loading…
Located: Loading…
Article (Journal) Online Resource -
2
Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response by Loibl, Sibylle (Author) , Schneeweiss, Andreas (Author) , Huober, J. (Author) , Braun, M. (Author) , Rey, J. (Author) , Blohmer, J. -U. (Author) , Furlanetto, J. (Author) , Zahm, D. -M. (Author) , Hanusch, C. (Author) , Thomalla, J. (Author) , Jackisch, C. (Author) , Staib, P. (Author) , Link, T. (Author) , Rhiem, K. (Author) , Solbach, C. (Author) , Fasching, P. A. (Author) , Nekljudova, V. (Author) , Denkert, C. (Author) , Untch, M. (Author) ,
Call Number: Loading…
Located: Loading…
Article (Journal) Online Resource -
3
Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study) by Fasching, Peter Andreas (Author) , Link, T. (Author) , Hauke, J. (Author) , Seither, F. (Author) , Jackisch, C. (Author) , Klare, P. (Author) , Schmatloch, S. (Author) , Hanusch, C. (Author) , Huober, J. (Author) , Stefek, A. (Author) , Seiler, S. (Author) , Schmitt, W. D. (Author) , Uleer, C. (Author) , Doering, G. (Author) , Rhiem, K. (Author) , Schneeweiss, Andreas (Author) , Engels, K. (Author) , Denkert, C. (Author) , Schmutzler, R. K. (Author) , Hahnen, E. (Author) , Untch, M. (Author) , Burchardi, N. (Author) , Blohmer, J. -U. (Author) , Loibl, S. (Author) ,
Call Number: Loading…
Located: Loading…
Article (Journal) Online Resource -
4
Reconstructing tumor history in breast cancer: signatures of mutational processes and response to neoadjuvant chemotherapy⋆ by Denkert, Carsten (Author) , Untch, M. (Author) , Benz, S. (Author) , Schneeweiss, Andreas (Author) , Weber, K. E. (Author) , Schmatloch, S. (Author) , Jackisch, C. (Author) , Sinn, Peter (Author) , Golovato, J. (Author) , Karn, T. (Author) , Marmé, Frederik (Author) , Link, T. (Author) , Budczies, Jan (Author) , Nekljudova, V. (Author) , Schmitt, W. D. (Author) , Stickeler, E. (Author) , Müller, V. (Author) , Jank, P. (Author) , Parulkar, R. (Author) , Heinmöller, E. (Author) , Sanborn, J. Z. (Author) , Schem, C. (Author) , Sinn, Bruno (Author) , Soon-Shiong, P. (Author) , van Mackelenbergh, M. (Author) , Fasching, P. A. (Author) , Rabizadeh, S. (Author) , Loibl, S. (Author) ,
Call Number: Loading…
Located: Loading…
Article (Journal) Online Resource -
5
Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo by Karn, Thomas (Author) , Denkert, C. (Author) , Weber, K. E. (Author) , Holtrich, U. (Author) , Hanusch, C. (Author) , Sinn, B. V. (Author) , Higgs, B. W. (Author) , Jank, P. (Author) , Sinn, Peter (Author) , Huober, J. (Author) , Becker, C. (Author) , Blohmer, J. -U. (Author) , Marmé, Frederik (Author) , Schmitt, W. D. (Author) , Wu, S. (Author) , van Mackelenbergh, M. (Author) , Müller, V. (Author) , Schem, C. (Author) , Stickeler, E. (Author) , Fasching, P. A. (Author) , Jackisch, C. (Author) , Untch, M. (Author) , Schneeweiss, Andreas (Author) , Loibl, S. (Author) ,
Call Number: Loading…
Located: Loading…
Article (Journal) Online Resource
Search Tools:
Related Subjects
neoadjuvant therapy
HER2-negative breast cancer
HRD
PARP inhibitor
RIBANNA
advanced breast cancer
breast cancer
carboplatinum
checkpoint inhibitor
conditional progression-free survival
conditional survival
durvalumab
early triple-negative breast cancer
exome sequencing
metastatic breast cancer
mutational signatures
neoadjuvant chemotherapy
neoadjuvant immune checkpoint inhibition
olaparib
prognosis
response
ribociclib
survival
triple negative breast cancer
tumor mutational burden
whole exome sequencing